51 search results for: quality of life

Clinical Assessment <b>of</b> Prurigo Nodularis

expert video

Clinical Assessment of Prurigo Nodularis

9 min

Dermatology

Join Dr. Nicholas Mollanazar as he discusses the diagnosis and assessment of prurigo nodularis.

ERS 2024 | Understanding the Complex Pathophysiology <b>of</b> COPD

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

ERS 2024 | Unraveling the Role <b>of</b> Type 2 Inflammation in COPD

expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

8 min

Pulmonology

Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.

How Can FeNO Support the Management <b>of</b> Pediatric Asthma?

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

expert video

Overview of EoE Pathophysiology and the Impact on Patient Burden

4 min

Gastroenterology

Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the pathophysiology and burden of EoE.

EoE Burden and Pathophysiology <b>of</b> Type 2 Inflammation

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Type 2 Inflammation Is a Significant Driver <b>of</b> Pediatric Severe Asthma

Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

ERS 2024 | The Role <b>of</b> IL-33 in COPD Patho and Its Impact on Disease Remodeling

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min

Pulmonology

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

35 min

Pulmonology

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, and discuss preclinical findings.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region